Data Foundry

Drug recalls 2023

Aripiprazole Tablets — Class II drug recall D-0539-2023

Ongoing recall by Ascend Laboratories, LLC, reported 2023-04-26, distributed nationwide. Out of specification (OOS) for Spectroscopic Identification test by IR.

Recall numberD-0539-2023
Product typeDrug
ClassificationClass II
StatusOngoing
Voluntary or mandatedVoluntary
Recalling firmAscend Laboratories, LLC, Parsippany, NJ, United States
Recall initiated2023-03-17
Classified2023-04-19
Reported by FDA2023-04-26
DistributedNationwide (US)
Quantity135 bottles
Reason classesspecification failure
NDC67877-0430, 67877-0430-01, 67877-0430-03, 67877-0430-05, 67877-0430-32, 67877-0430-33, 67877-0430-38, 67877-0431, 67877-0431-01, 67877-0431-03, 67877-0431-05, 67877-0431-32, 67877-0431-33, 67877-0431-38, 67877-0432, 67877-0432-01, 67877-0432-03, 67877-0432-05, 67877-0432-32, 67877-0432-33, 67877-0432-38, 67877-0433, 67877-0433-01, 67877-0433-03, 67877-0433-05 and 15 more
Lot numbers22143120
Expiration dates2024-06-20

Product

Aripiprazole Tablets, USP, 20 mg, Rx Only, Packaged in 500-count bottle Manufactured by: Alkem Laboratories Ltd., INDIA Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054, NDC#: 67877-434-05

Reason for recall

Out of specification (OOS) for Spectroscopic Identification test by IR.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0539-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.